Better diagnostics, better treatment

Saving lives through antibiotic sensitivity precision diagnostics

Solution

At Astek Diagnostics, we are creating the JIDDU system, an innovative clinical diagnostics platform that offers infection confirmation for urinary tract infections (UTIs) and antibiotic sensitivity indication within 1 hour.

The JIDDU system greatly improves diagnostic speed and accuracy, thereby reducing patient complications and pain, as well as lowering healthcare costs. It represents a significant leap forward in patient care that allows for much more timely and accurate treatment than the current standard of care. This ultimately leads to saving lives, given that 25% of sepsis cases are caused by UTIs.

Given that women get UTIs up to 30 times more often than men, the development and deployment of the JIDDU system would have major implications on FemHealth.

"It has become clear that our current UTI diagnostic approach, which informs treatment, is not only slow but also scientifically flawed. As a Rehabilitation Medicine physician-scientist working with patients particularly vulnerable to UTIs, I lack reliable point-of-care tools to guide clinical decision-making. Consequently, the standard practice often involves 'guessing' the appropriate antibiotic and waiting days for confirmation or to adjust the treatment. Astek's Jiddu platform has the potential to transform this process by removing the guesswork at the point of care, enabling earlier and more accurate antibiotic treatment. This not only accelerates patient recovery but also reduces unnecessary antibiotic exposure. The benefits extend beyond individual patients to broader societal gains, including lower healthcare costs and reduced antimicrobial resistance."

Suzanne Lynn Groah, MD, MSPH

MedStar National Rehabilitation Hospital

UTIs are among the leading precursors of antimicrobial resistance (AMR)

AMR is among the biggest global health threats

Problem
A leap forward from the current “gold standard” of UTI diagnostics and treatment

Rapid and actionable results within 1 hour

Solution
Going beyond UTI diagnostics and treatment

Developing a universal diagnostic system which tests 4 sample types

Grand vision
Current focus
Urine
In development
CSF
Effluent
Blood
How it started

Mustafa Al Adhami, PhD

CEO at Astek Diagnostics

In 2021, the growing issue of antibiotic resistant UTIs became personal for Mustafa. His grandfather was suffered from agonizing pain for days before being diagnosed with a UTI and being treated with the right antibiotic. Mustafa’s family felt entirely helpless during this experience.

Recognizing the need for a solution, Mustafa founded Astek Diagnostics. Ever since, he has been dedicated to revolutionizing the way antibiotics are prescribed to patients.

Today, in partnership with key healthcare institutions such, including The University of Maryland Medical Center and MedStar Health, Astek Diagnostics has achieved exceptional initial results and is well on its way to a market entry in 2025.

About Astek